J&J Casts Aside HRSA Warnings, Will Press Forward With 340B Rebate Model

By Gabrielle Wanneh / August 27, 2024 at 3:57 PM

Johnson & Johnson is standing firm on its transition to a new 340B drug rebate model even though the Health Resources and Services Administration warned the company last week the model is inconsistent with 340B statute and has not been approved by the HHS secretary, the drug maker told Inside Health Policy Tuesday (Aug. 27).


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.